BIOMAT Database Logo BIOMAT Database Logo

Efficacy and safety of twice- vs once-daily dosing of lisinopril for hypertension. 2017

Tiffany Tsai, and Miranda E Kroehl, and Steven M Smith, and Angela M Thompson, and Isabella Y Dai, and Katy E Trinkley
Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

This retrospective cohort study compared administration of lisinopril twice daily and once daily for hypertension. Data were collected from an ambulatory electronic health record between 2011 and 2014. Patients previously receiving lisinopril 20 mg were placed into the once-daily cohort if changed to 40 mg once daily or into the twice-daily cohort if changed to 20 mg twice daily. Efficacy outcome measures were change in systolic blood pressure and diastolic blood pressure and achievement of blood pressure control (<140/90 mm Hg). Of 90 patients included (45 per cohort), the mean age was 61.8 years and 17.8% were black. Once- and twice-daily administrations were associated with blood pressure reductions of 6.2/1.5 mm Hg and 16.5/5.9 mm Hg, with a 10.2/4.3 mm Hg greater reduction with twice-daily administration (systolic blood pressure, P=.016; diastolic blood pressure, P=.068). Twice-daily lisinopril dosing was associated with greater systolic blood pressure reductions compared with the same total daily dose administered once daily.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

Tiffany Tsai, and Miranda E Kroehl, and Steven M Smith, and Angela M Thompson, and Isabella Y Dai, and Katy E Trinkley
Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety.
January 2020, PloS one,
Tiffany Tsai, and Miranda E Kroehl, and Steven M Smith, and Angela M Thompson, and Isabella Y Dai, and Katy E Trinkley
Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension.
January 1990, European journal of clinical pharmacology,
Tiffany Tsai, and Miranda E Kroehl, and Steven M Smith, and Angela M Thompson, and Isabella Y Dai, and Katy E Trinkley
Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
November 1994, Archives of internal medicine,
Tiffany Tsai, and Miranda E Kroehl, and Steven M Smith, and Angela M Thompson, and Isabella Y Dai, and Katy E Trinkley
Efficacy of once-daily lisinopril monotherapy in systemic hypertension.
February 1993, Clinical cardiology,
Tiffany Tsai, and Miranda E Kroehl, and Steven M Smith, and Angela M Thompson, and Isabella Y Dai, and Katy E Trinkley
Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing.
December 1990, Atherosclerosis,
Tiffany Tsai, and Miranda E Kroehl, and Steven M Smith, and Angela M Thompson, and Isabella Y Dai, and Katy E Trinkley
Evaluation of the Safety and Efficacy of Enoxaparin Once-Daily Versus Twice-Daily Dosing for Prophylaxis in Pediatric Patients.
April 2024, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG,
Tiffany Tsai, and Miranda E Kroehl, and Steven M Smith, and Angela M Thompson, and Isabella Y Dai, and Katy E Trinkley
Deciding between once- and twice-daily dosing.
April 1996, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Tiffany Tsai, and Miranda E Kroehl, and Steven M Smith, and Angela M Thompson, and Isabella Y Dai, and Katy E Trinkley
Twice-daily vs. once-daily inpatient dithranol for psoriasis.
November 2002, Clinical and experimental dermatology,
Tiffany Tsai, and Miranda E Kroehl, and Steven M Smith, and Angela M Thompson, and Isabella Y Dai, and Katy E Trinkley
Trough to peak ratio of once-daily lisinopril and twice-daily captopril in patients with essential hypertension.
January 1998, Journal of human hypertension,
Tiffany Tsai, and Miranda E Kroehl, and Steven M Smith, and Angela M Thompson, and Isabella Y Dai, and Katy E Trinkley
Impact of once- and twice-daily dosing regimens on adherence and overall safety.
June 2004, The AIDS reader,
Copied contents to your clipboard!